Kyoko Kobayashi1, Etsuko Nakagami-Yamaguchi2, Akira Hayakawa3, Souichi Adachi4, Junichi Hara5, Sadao Tokimasa6, Hideaki Ohta7, Yoshiko Hashii8, Takeshi Rikiishi9, Machiko Sawada10, Kikuko Kuriyama11, Urara Kohdera12, Kiyoko Kamibeppu13, Hirohide Kawasaki14, Megumi Oda15, Hiroki Hori16. 1. Department of Child Health Nursing, St Luke's International University Graduate School of Nursing Science, Chuo, Japan. 2. Department of Medical Quality and Safety Science, Osaka City University Graduate School of Medicine, Abeno, Japan. 3. Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan. 4. Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Sakyo, Kyoto, Japan. 5. Department of Pediatric Hematology Oncology, Children's Medical Cancer Osaka City General Hospital, Toshima, Japan. 6. Department of Pediatrics, Osaka City University Graduate School of Medicine, Abeno, Japan. 7. Department of Pediatrics, Higashitoyonaka Watanabe Hospital, Toyonaka City, Japan. 8. Department of Developmental Medicine, Osaka University Graduate School of Medicine, Suita, Japan. 9. Department of Pediatrics, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. 10. Department of Pediatrics, Takashima Municipal Hospital, Takashima, Shiga, Japan. 11. Aichi Children's Health and Medical Cancer, Obu, Aichi, Japan. 12. Nakano Children's Hospital, Asahi, Japan. 13. Department of Family Nursing, Graduate School of Medicine, University of Tokyo, Bunkyo, Tokyo, Japan. 14. Department of Pediatrics, Kansai Medical University, Hirakata, Osaka, Japan. 15. Graduate School of Health Sciences, Okayama University, Kita, Okayama, Japan. 16. Mie University Graduate School of Medicine, Tsu, Mie, Japan.
Abstract
BACKGROUND: Quality of life (QOL) as a treatment outcome has not yet been evaluated among patients receiving a specific treatment regimen by treatment phase in a consistent manner. This exploratory cross-sectional study evaluated the QOL of children with acute lymphoblastic leukemia (ALL) receiving one of the most popular treatment regimens in Japan (Japan Association of Childhood Leukemia Study ALL-02 revised protocol). METHODS: Children aged 5-18 years with newly diagnosed B-cell precursor ALL were included. The Pediatric Quality of Life Inventory™ 4.0 Generic Core Scales (PedsQL-J) were completed by children with ALL and their siblings, as well as by age- and sex-matched healthy controls. PedsQL Cancer Module (PedsQL-C) scores were also collected from children with ALL. RESULTS: QOL in children with ALL of the consolidation phase group was significantly decreased compared with that of healthy controls, except in the area of emotional functioning. Regarding the maintenance phase group, QOL impairment was noted in the physical and school functioning, but no differences were noted in social functioning. The off-treatment group had a large effect size only for physical functioning, and the social functioning score was even better in children with ALL than in matched controls. QOL of children with ALL differed with treatment phase. Effect size varied with function and treatment phase. CONCLUSIONS: QOL may change with the progression of treatment, and the timing of these changes varied according to function and problem.
BACKGROUND: Quality of life (QOL) as a treatment outcome has not yet been evaluated among patients receiving a specific treatment regimen by treatment phase in a consistent manner. This exploratory cross-sectional study evaluated the QOL of children with acute lymphoblastic leukemia (ALL) receiving one of the most popular treatment regimens in Japan (Japan Association of Childhood Leukemia Study ALL-02 revised protocol). METHODS:Children aged 5-18 years with newly diagnosed B-cell precursor ALL were included. The Pediatric Quality of Life Inventory™ 4.0 Generic Core Scales (PedsQL-J) were completed by children with ALL and their siblings, as well as by age- and sex-matched healthy controls. PedsQL Cancer Module (PedsQL-C) scores were also collected from children with ALL. RESULTS: QOL in children with ALL of the consolidation phase group was significantly decreased compared with that of healthy controls, except in the area of emotional functioning. Regarding the maintenance phase group, QOL impairment was noted in the physical and school functioning, but no differences were noted in social functioning. The off-treatment group had a large effect size only for physical functioning, and the social functioning score was even better in children with ALL than in matched controls. QOL of children with ALL differed with treatment phase. Effect size varied with function and treatment phase. CONCLUSIONS: QOL may change with the progression of treatment, and the timing of these changes varied according to function and problem.
Authors: Andrew Garas; Louise A McLean; Cinzia R De Luca; Peter Downie; Maria C McCarthy Journal: Support Care Cancer Date: 2019-03-21 Impact factor: 3.603
Authors: Carol C Choo; Peter K H Chew; Pinhong Tan; Jessica Q Choo; Amanda M H Choo; Roger C Ho; Thuan Chong Quah Journal: Int J Environ Res Public Health Date: 2019-06-12 Impact factor: 3.390